Efficacy of Botulinum Toxin for the Treatment of Dystonia Associated With Parkinson's Disease and Atypical Parkinsonism: a Monocentric Cohort Study With Patient Reported Outcome

Status: Completed
Location: See location...
Study Type: Observational
SUMMARY

Dystonia is a disabling symptom affecting both patients with idiopathic Parkinson's disease (PD) and atypical parkinsonism (AP). Botulinum toxinum (BoNT), by blocking muscle contraction, is a possible treatment for focal dystonia. The benefit of BoNT treatment has been proven in some focal dystonia associated with PD or AP. The investigators aim to give an overview of the efficacy of BoNT in a variety of focal dystonia in a large cohort of parkinsonian patients.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: No
View:

• Diagnosed Parkinson's disease or Atypical Parkinsonism

• Age > 18 years

• Reported dystonia

• At least 1 injection with Botulinum toxin realized

Locations
Other Locations
France
Avicenne Hospital
Bobigny
Time Frame
Start Date: September 1, 2017
Completion Date: February 11, 2021
Participants
Target number of participants: 63
Treatments
Patients with dystonia secondary to atypical Parkinsonism or Parkinson's disease
Patients with dystonia secondary to idiopathic Parkinson's disease or atypical parkinsonism and treated with BoNT
Patients with atypical Parkinsonism or Parkinson's disease and no dystonia
Patients with idiopathic Parkinson's disease or atypical parkinsonism and without reported dystonia
Sponsors
Leads: Hospital Avicenne
Collaborators: Assistance Publique - Hôpitaux de Paris

This content was sourced from clinicaltrials.gov